SCHEMBL5709588

SCHEMBL5709588

O=C(O)C(CC(=O)N1CCOCC1)Cc1cccc2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.49
MEN1 O00255 3/20 0.49
ALDH1A1 P00352 4/20 0.46
HPGD P15428 1/20 0.46
KDM4E B2RXH2 4/20 0.46
TSHR P16473 2/20 0.46
HSD17B10 Q99714 1/20 0.46
PIN1 Q13526 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
REN P00797 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MAPT P10636 2/20 0.45
FKBP1A P62942 2/20 0.44
CTNNB1 P35222 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2295759 1.00 KMT2A (0.49) KMT2AMEN1ALDH1A1HPGDKDM4E
SCHEMBL7301131 1.00 KMT2A (0.49) KMT2AMEN1ALDH1A1HPGDKDM4E
SCHEMBL7433845 0.89 KDM4E (0.45) KMT2AMEN1ALDH1A1HPGDKDM4E
SCHEMBL11981992 0.89 REN (0.48) KMT2AMEN1ALDH1A1HPGDKDM4E
SCHEMBL13840602 0.89 REN (0.48) KMT2AMEN1ALDH1A1HPGDKDM4E
SCHEMBL7433838 0.89 KDM4E (0.45) KMT2AMEN1ALDH1A1HPGDKDM4E
SCHEMBL10751934 0.89 CTNNB1 (0.47) KMT2AMEN1ALDH1A1HPGDKDM4E
SCHEMBL7289410 0.89 CTNNB1 (0.47) KMT2AMEN1ALDH1A1HPGDKDM4E
SCHEMBL421814 0.88 REN (0.48) KMT2AMEN1ALDH1A1HPGDKDM4E
SCHEMBL13839332 0.88 REN (0.48) KMT2AMEN1ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1712227-A1 Amino diols useful in the treatment of Alzheimer's disease Elan Pharmaceuticals, Inc. (US) 2006-10-18 EP claimed
US-20050080141-A1 Amino diols useful in the treatment of alzheimer's disease SCHOSTAREZ HEINRICH J (US) 2005-04-14 US claimed
EP-1448177-A1 AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2004-08-25 EP claimed
WO-2003043618-A2 AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2003-05-30 WO claimed
EP-0470702-B1 An optically active morpholino oxobutyric acid hydroxy binaphthalene derivative and its preparation TAKASAGO PERFUMERY CO LTD (JP) 1995-09-27 EP claimed
JP-4069384-A None JP disclosed
EP-1712227-A1 Amino diols useful in the treatment of Alzheimer's disease Elan Pharmaceuticals, Inc. (US) 2006-10-18 EP disclosed
US-20050080141-A1 Amino diols useful in the treatment of alzheimer's disease SCHOSTAREZ HEINRICH J (US) 2005-04-14 US disclosed
EP-1448177-A1 AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2004-08-25 EP disclosed
WO-2003043618-A2 AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed
EP-0470702-B1 An optically active morpholino oxobutyric acid hydroxy binaphthalene derivative and its preparation TAKASAGO PERFUMERY CO LTD (JP) 1995-09-27 EP disclosed
US-5428054-A Renin inhibitor G. D. SEARLE & CO. (US) 1995-06-27 US disclosed
EP-0310072-A2 Non-peptidyl beta-succinamidoacyl aminodiols as anti-hypertensive agents G.D. Searle & Co. (US) 1989-04-05 EP disclosed
EP-0281316-A2 Renin inhibitors YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1988-09-07 EP disclosed
EP-0278158-A2 Renin inhibitors containing phenylalanyl-histidine replacements MERCK & CO. INC. (US) 1988-08-17 EP disclosed
US-4711958-A HYPOTENSIVE AGENTS KISSEI PHARMACEUTICAL CO., LTD. (JP) 1987-12-08 US disclosed
EP-0244083-A2 Amino acid derivatives Kissei Pharmaceutical Co. Ltd. (JP) 1987-11-04 EP disclosed
US-4656269-A RENIN INHIBITORY EFFECT WHEN ADMINISTERING ORALLY; HYPOTENSIVE AGENTS KISSEI PHARMACEUTICAL CO., LTD. (JP) 1987-04-07 US disclosed
EP-0216539-A2 Novel amino acid derivatives Kissei Pharmaceutical Co. Ltd. (JP) 1987-04-01 EP disclosed
EP-0200406-A2 Novel amino acid derivatives Kissei Pharmaceutical Co. Ltd. (JP) 1986-11-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080141-A1 Amino diols useful in the treatment of alzheimer's disease BACE1, BACE2, APP KMT2A 3385/4885MEN1 2310/4885ALDH1A1 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.